Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bavarian Nordic, BMS in Drug Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Bavarian Nordic, BMS in Drug Supply Pact

BMS will supply OPDIVO for NSCLC Clinical Study

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bavarian Nordic has entered a drug supply agreement with Bristol-Myers Squibb, under which BMS will supply OPDIVO (nivolumab) for use in a clinical study exploring the benefit of combining CV301 with OPDIVO in patients with previously treated non-small cell lung cancer (NSCLC). OPDIVO is approved for treatment of NSCLC in the second line setting, among other indications.
 
CV301 targets two tumor-associated antigens, CEA and MUC-1, which are over-expressed in major cancer types, including lung, bladder and colorectal cancer.
 
Preclinical data shows the ability of CV301 to upregulate PD-L1 by mounting an immune response against a tumor target.
 
“We are extremely excited to announce this agreement. While we have discussed the potential benefit of combining our cancer vaccines with checkpoint inhibitors for some time, this is now within reach as we have once again been able to strike an agreement with the leading immune-oncology company in the world, this time to explore the potential synergy between our programs to benefit patients with lung cancer. We look forward to the initiation of this study later this year,” said Paul Chaplin, president and chief executive officer of Bavarian Nordic.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics